178 related articles for article (PubMed ID: 36286729)
21. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK; Kubicki T; Raje N; Vij R; Reece D; Berdeja J; Derman BA; Rosenbaum CA; Richardson P; Gurbuxani S; Major S; Wolfe B; Stefka AT; Stephens L; Tinari KM; Hycner T; Rojek AE; Dytfeld D; Griffith KA; Zimmerman TM; Jakubowiak AJ
Blood; 2020 Nov; 136(22):2513-2523. PubMed ID: 32735641
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Onda Y; Kanda J; Kaneko H; Shimura Y; Fuchida SI; Nakaya A; Itou T; Yamamura R; Tanaka H; Shibayama H; Shimazu Y; Uchiyama H; Yoshihara S; Adachi Y; Matsuda M; Hanamoto H; Uoshima N; Kosugi S; Ohta K; Yagi H; Kanakura Y; Matsumura I; Hino M; Nomura S; Shimazaki C; Takaori-Kondo A; Kuroda J;
Ther Adv Hematol; 2022; 13():20406207221104584. PubMed ID: 35785245
[TBL] [Abstract][Full Text] [Related]
23. Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.
Leleu X; Katodritou E; Kuehr T; Terpos E; Caers J; Zambello R; Brescianini A; Liang T; Wetten S; Badelita SN
EJHaem; 2023 Feb; 4(1):174-183. PubMed ID: 36819146
[TBL] [Abstract][Full Text] [Related]
24. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Biran N; Siegel D; Berdeja JG; Raje N; Cornell RF; Alsina M; Kovacsovics T; Fang B; Kimball AS; Landgren O
Am J Hematol; 2019 Jul; 94(7):794-802. PubMed ID: 31021005
[TBL] [Abstract][Full Text] [Related]
25. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Morabito F; Zamagni E; Conticello C; Pavone V; Palmieri S; Bringhen S; Galli M; Mangiacavalli S; Derudas D; Rossi E; Ria R; Catalano L; Tacchetti P; Mele G; Vincelli ID; Martino EA; Vigna E; Bruzzese A; Mendicino F; Botta C; Mele A; Pantani L; Rocchi S; Garibaldi B; Cascavilla N; Ballanti S; Tripepi G; Frigeri F; Falcone AP; Cangialosi C; Reddiconto G; Farina G; Barone M; Rizzello I; Iaccino E; Mimmi S; Curci P; Gamberi B; Musto P; De Stefano V; Musso M; Petrucci MT; Offidani M; Di Raimondo F; Boccadoro M; Cavo M; Neri A; Gentile M
Front Oncol; 2022; 12():890376. PubMed ID: 35924160
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
27. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
Palmieri S; Rocco S; Vitagliano O; Catalano L; Cerchione C; Vincelli ID; Scopelliti A; Gentile M; Farina G; Barone M; Gagliardi A; Esposito D; Arcamone M; Amico V; Fontana R; Sementa A; Sica A; Svanera G; Pane F; Ferrara F
Ann Hematol; 2020 Dec; 99(12):2903-2909. PubMed ID: 32583088
[TBL] [Abstract][Full Text] [Related]
28. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ
JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Mangiacavalli S; Cartia CS; Galli M; Pezzatti S; Belotti A; Fazio F; Mina R; Marcatti M; Cafro A; Zambello R; Paris L; Barilà G; Olivares C; Pompa A; Mazza R; Farina F; Soldarini M; Benvenuti P; Pagani G; Palumbo M; Masoni V; Ferretti VV; Klersy C; Arcaini L; Petrucci MT
Haematologica; 2023 Mar; 108(3):833-842. PubMed ID: 36200419
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Kawaji-Kanayama Y; Kobayashi T; Muramatsu A; Uchiyama H; Sasaki N; Uoshima N; Nakao M; Takahashi R; Shimura K; Kaneko H; Kiyota M; Wada K; Chinen Y; Hirakawa K; Fuchida SI; Shimazaki C; Matsumura-Kimoto Y; Mizutani S; Tsukamoto T; Shimura Y; Horiike S; Taniwaki M; Kuroda J;
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1476. PubMed ID: 34124862
[TBL] [Abstract][Full Text] [Related]
31. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Avet-Loiseau H; Fonseca R; Siegel D; Dimopoulos MA; Špička I; Masszi T; Hájek R; Rosiñol L; Goranova-Marinova V; Mihaylov G; Maisnar V; Mateos MV; Wang M; Niesvizky R; Oriol A; Jakubowiak A; Minarik J; Palumbo A; Bensinger W; Kukreti V; Ben-Yehuda D; Stewart AK; Obreja M; Moreau P
Blood; 2016 Sep; 128(9):1174-80. PubMed ID: 27439911
[TBL] [Abstract][Full Text] [Related]
33. Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea.
Lee HK; Jang HY; Kim IW; Oh JM
J Cancer Res Clin Oncol; 2024 May; 150(5):266. PubMed ID: 38769166
[TBL] [Abstract][Full Text] [Related]
34. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
[TBL] [Abstract][Full Text] [Related]
35. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Tan CR; Derkach A; Nemirovsky D; Ciardiello A; Diamond B; Hultcrantz M; Hassoun H; Mailankody S; Shah U; Maclachlan K; Patel D; Lahoud OB; Landau HJ; Chung DJ; Shah GL; Scordo M; Giralt SA; Lesokhin A; Usmani SZ; Landgren O; Korde N
Blood Cancer J; 2023 Jul; 13(1):112. PubMed ID: 37491332
[TBL] [Abstract][Full Text] [Related]
37. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
Duarte PJ; Schutz NP; Ochoa P; Yantorno S; Orlando S; Lopresti S; Zabaljauregui S; Aizpurua F; Shanley C; Giannini E; Garate G; Foncuberta C; Milone J; Riveros D; Fantl D
Expert Rev Hematol; 2021 Mar; 14(3):315-322. PubMed ID: 33541156
[TBL] [Abstract][Full Text] [Related]
38. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Richter J; Lin PL; Garcia-Horton V; Guyot P; Singh E; Zhou ZY; Sievert M; Taiji R
Cancer Med; 2023 Apr; 12(7):8005-8017. PubMed ID: 36726287
[TBL] [Abstract][Full Text] [Related]
39. Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
Conticello C; Romano A; Del Fabro V; Martino EA; Calafiore V; Sapienza G; Leotta V; Parisi MS; Markovic U; Garibaldi B; Leotta S; Cotzia E; Innao V; Mannina D; Neri S; Musso M; Scalone R; Cangialosi C; Acquaviva F; Cardinale G; Merenda A; Maugeri C; Uccello G; Poidomani M; Longo G; Carlisi M; Tibullo D; Di Raimondo F
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31248142
[No Abstract] [Full Text] [Related]
40. Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
DerSarkissian M; Cranmer H; Dabora J; Bocharova I; Cherepanov D; Cheng M; Bhak RH; Duh MS
Hematology; 2023 Dec; 28(1):2156731. PubMed ID: 36607147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]